Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5671610 | 0.99 | HRH3 (0.55) | HRH3CHRNA7HTR3AALDH1A1POLB | |
| Fumaric Acid SCHEMBL5217806 | 0.90 | HRH3 (0.48) | HRH3 | |
| SCHEMBL2641500 | 0.81 | HRH3 (0.40) | HRH3CHRNA7HTR3AALDH1A1POLB | |
| SCHEMBL2638277 | 0.81 | HRH3 (0.39) | HRH3CHRNA7 | |
| SCHEMBL2638809 | 0.81 | HRH3 (0.39) | HRH3CHRNA7 | |
| SCHEMBL2638197 | 0.81 | CHRNA7 (0.46) | HRH3CHRNA7HTR3A | |
| SCHEMBL2638705 | 0.80 | CHRNA7 (0.41) | HRH3CHRNA7HTR3A | |
| SCHEMBL2638877 | 0.80 | CHRNA7 (0.43) | HRH3CHRNA7HTR3A | |
| SCHEMBL2641513 | 0.80 | HRH3 (0.38) | HRH3CHRNA7 | |
| SCHEMBL2638937 | 0.79 | CHRNA7 (0.44) | HRH3CHRNA7HTR3AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4711391-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| EP-1785425-A2 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | NeuroSearch A/S (DK) | 2007-05-16 | — | — | EP | claimed |
| US-20060122172-A1 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | DANPET AB (SE) | 2006-06-08 | — | — | US | claimed |
| EP-1551835-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NeuroSearch A/S (DK) | 2005-07-13 | — | — | EP | claimed |
| WO-2004029053-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2004-04-08 | — | — | WO | claimed |
| EP-1785425-B1 | 1,4-Diazabicycloalkane derivatives, their preparation and use | NEUROSEARCH AS (DK) | 2009-03-25 | — | — | EP | disclosed |
| US-7220741-B2 | 1,4-diazabicycloalkane derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| EP-1785425-A2 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | NeuroSearch A/S (DK) | 2007-05-16 | — | — | EP | disclosed |
| EP-1551835-B1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2007-02-14 | — | — | EP | disclosed |
| US-20060122172-A1 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | DANPET AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1551835-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NeuroSearch A/S (DK) | 2005-07-13 | — | — | EP | disclosed |
| EP-1451189-B1 | 4-(1,3,4-THIADIAZOL-2-YL)-1,4-DIAZABICYCLO- 3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2005-05-25 | — | — | EP | disclosed |
| US-20050020599-A1 | 4-(1,3,4,-thiadiazol-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2005-01-27 | — | — | US | disclosed |
| WO-2004029053-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020599-A1 | 4-(1,3,4,-thiadiazol-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof | CHRNA2, CHRNA1, CHRNA5 | HRH3 497/4885CHRNA7 6/4885HTR3A 100/4885 |
| US-20060122172-A1 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | CHRNA5, CHRNA7, CHRNA6 | HRH3 672/4885CHRNA7 2/4885HTR3A 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.